Literature DB >> 9808413

The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues.

L Thorsteinsson1, G M O'Dowd, P M Harrington, P M Johnson.   

Abstract

Three of the proteins protecting cells from autologous lysis by complement are: membrane cofactor protein (MCP; CD46), an inhibitor of the membrane attack complex formation (CD59), and decay accelerating factor (DAF; CD55). We have investigated the expression of these proteins in breast and colorectal carcinoma by immunohistochemistry and immunoblotting of breast tissue for CD46. CD46 was consistently and strongly expressed in the epithelial compartment in 26/28 ductal carcinomas of the breast, 9/9 fibroadenomas, and 9/11 cases of control non-neoplastic breast tissue. CD59 showed a similar degree of expression in the fibroadenomas (9/9), but was less strongly expressed in carcinomatous (22/28) and control (5/11) tissues. In marked contrast, no CD55 expression was detected in tissue from 15 ductal carcinomas. Immunoblotting of breast tissue for CD46 showed the same size of the molecule as for lymphocytes. It had however considerably stronger expression in tumour tissue than in non-neoplastic tissue. CD46 and CD59 were either lacking or only weakly expressed in the epithelial component of control colorectal mucosa: 2/15 and 5/15, respectively. In contrast, tissue samples from colorectal adenocarcinomas showed clear staining for both CD59 (10/18) and, more markedly, CD46 (15/18). There was no association between the pattern or intensity of CD46 and CD59 expression and tumour differentiation. As the complement regulatory proteins CD46 and CD59 are also strongly expressed by trophoblast at the feto-maternal tissue interface, these results support the concept that similar mechanisms are employed both by the genetically dissimilar fetus and certain tumours to evade immune attack by their host.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9808413     DOI: 10.1111/j.1699-0463.1998.tb00233.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  30 in total

Review 1.  Use of preferentially replicating bacteria for the treatment of cancer.

Authors:  M Sznol; S L Lin; D Bermudes; L M Zheng; I King
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack.

Authors:  O B Spiller; O Criado-García; S Rodríguez De Córdoba; B P Morgan
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

3.  Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors.

Authors:  Dmitry M Shayakhmetov; Zong-Yi Li; Shaoheng Ni; André Lieber
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

4.  Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobs.

Authors:  Dmitry M Shayakhmetov; Andrea M Eberly; Zong-Yi Li; André Lieber
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Localization of regions in CD46 that interact with adenovirus.

Authors:  Anuj Gaggar; Dmitry M Shayakhmetov; M Kathryn Liszewski; John P Atkinson; André Lieber
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

6.  Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons.

Authors:  Shaoheng Ni; Kathrin Bernt; Anuj Gaggar; Zong-Yi Li; Hans-Peter Kiem; André Lieber
Journal:  Hum Gene Ther       Date:  2005-06       Impact factor: 5.695

Review 7.  Protein engineering to target complement evasion in cancer.

Authors:  Darrick Carter; André Lieber
Journal:  FEBS Lett       Date:  2013-11-14       Impact factor: 4.124

8.  Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection.

Authors:  Juan Carlos Varela; Carl Atkinson; Robert Woolson; Thomas E Keane; Stephen Tomlinson
Journal:  Int J Cancer       Date:  2008-09-15       Impact factor: 7.396

9.  Chimeric adenoviral vectors incorporating a fiber of human adenovirus 3 efficiently mediate gene transfer into prostate cancer cells.

Authors:  Miho Murakami; Hideyo Ugai; Natalya Belousova; Alexander Pereboev; Paul Dent; Paul B Fisher; Maaike Everts; David T Curiel
Journal:  Prostate       Date:  2010-03-01       Impact factor: 4.104

10.  A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy.

Authors:  Hongjie Wang; Ying Liu; Zong-Yi Li; Xiaolong Fan; Akseli Hemminki; André Lieber
Journal:  Blood       Date:  2009-11-12       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.